Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
for
Leukemia, B-Cell
Location: Houston TX
Sponsor: Baylor College of Medicine
Sex: All
Age: 1 - 25
Code: NCT05010564
Phase1, Recruiting
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
for
Acute Lymphoblastic Leukemia
Location: Duarte CA
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT06735690
Early_phase1, Recruiting
Interested in new lymphoma trials?
Get alerts for new trials in your area by subscribing now
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Location: Boston MA, New Brunswick NJ, Morristown NJ,
Sponsor: Sumitomo Pharma America, Inc.
Sex: All
Age: 12+
Code: NCT04988555
Phase1, Phase2, Recruiting
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
for
Leukemia, Myeloid, Chronic, Myeloid Leukemia,
Location: Baltimore MD, Toronto, Augusta GA, Cleveland OH,
Sponsor: Ascentage Pharma Group Inc.
Sex: All
Age: 18+
Code: NCT04260022
Phase1, Recruiting
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
for
Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 0+
Code: NCT03425526
Phase1, Recruiting
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
for
Acute Lymphoblastic Leukemia
Location: Los Angeles CA
Sponsor: University of Southern California
Sex: All
Age: 18+
Code: NCT03568266
Recruiting
International Rare Histiocytic Disorders Registry (IRHDR)
for
Rare Histiocytic Disorders (RHDs),
Location: Boston MA, New York NY, Toronto, Pittsburgh PA,
Sponsor: The Hospital for Sick Children
Sex: All
Age: 0+
Code: NCT02285582
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy